2Iskandar S B, Guha B, Krishnaswamy G, et al. Acinetobacter baumannii pneumonia: a case report and review of the literature[J]. Tenn Med, 2003, 96(9): 419-422.
3PodnosYD, CinatME, WilsonSE, etal. Eradication of multidrug resistant Acinetobacter from an intensive care unit[J]. Surg Infect (Larchmt), 2001, 2(4): 297-301.
4Cavallo J D, Fabre R, Gauabe E. Which betalactam antibiotic use as a .marker of multiresistance in Pseudomonas aeruginosa [ J ].Pathol Biot (Paris), 2003, 51 (8 - 9): 460 - 463.
5Cunha B A. Antibiotic resistance[J]. Med Clin North Amer,2000, 84(6): 1407- 1429.
6Cunha B A. Pseudomonas aeruginosa: resistance and therapy[ J ].Semin Resp Infect, 2002, 17(3): 231-239.
7Carsenti-Etesse H, Cavallo J D, Roger P M, et al. Effect of β-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa [J]. Chirurgia (Bucur), 2002, 97(2):151 - 159.
8Johnson D M, Biedenbach D J, Jones R N. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections[J]. Diagn Microbiol Infect Dis, 2002, 43( 1 ): 49- 60.
9Gibb A P, Tribuddhaeat C, Moore RA, et al. Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new bla (IMP) allele, ble ( IMP-7 ) [ J ]. Antimicrob Agents Chemother, 2002, 46( 1 ): 255 - 258.
10Regal R E, DePestel D D, VandenBussche H L. The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to β-lactams in a large teaching hospital[J]. Pharmacother, 2003, 23(5): 618-624.
二级参考文献31
1[1]Craig W A. Pharmacokinetic/pharmacodynamic parameters:rationale for antibacterial dosing of mice and men[J]. Clin lnfect Dis, 1998, 26: 1-12.
2[2]Nightingale C H, Murakawa T, Ambrose P G, et al. Antimicrobial pharmacodynamics in theory and clinical practice[M]. New York: Marcel Dekker, InC. 2002. 385-408.
3[3]Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies[J]. Clin lnfect Dis, 2001, 33: 147-156.
4Tsakris A, Pournaras S, Woodford N, et al. Outbreak d infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol, 2000.38: 1290-1292.
5Poirel L, Naas T, Nicolas D, et al. Characterization d VIM-2, a carbapanem-hydrolyzing metallo-beta-lactamase and its plasmid-and integron-borne gene from a Psedomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother. 2000.44: 891-897.
6Yah J, Hsueh P, Ko W, et al. Metallo-beta-lactamase in clinical Psedumonas isolates in Taiwan and identification d VIM-3, a novel variant of VIM-2 enzyme. Antimicrob Agents Chemother, 2001,45 :2224-2228.
7Yum JH, Yi K, Lee H, et al. Molecular characterization of metallobeta-lactamase-producing Acinetobacter bsumannii and Acinetobacter genomospecies 3 from Korea: identification of two new integrons carrying the bla (VIM-2) gene cassettes. J Antimicrob Chemother,2002, 49: 837-840.
8Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother, 2000, 44:1556-1561.
9Afzal-Shah M,Woodford N,Liermore DM,Characterization of OXA-25,OXA-26,and OXA-27,molecular class D bet-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii.Antimicrob Agents Chemother,2001,45:583-588.
10Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect, 2002, 8: 321-331.
